Cargando…

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management

Globally, endometrial cancer is the sixth leading cause of female cancer-related deaths. Non-atypical endometrial hyperplasia (EH), has a lifetime progression rate to endometrial cancer ranging from less than 5%, if simple without atypia, to 40%, if complex with atypia. Site specific, long-acting in...

Descripción completa

Detalles Bibliográficos
Autor principal:	Nwanodi, Oroma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618158/ https://www.ncbi.nlm.nih.gov/pubmed/28698465 http://dx.doi.org/10.3390/healthcare5030030

Ejemplares similares

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis
por: Shao, Fengping, et al.
Publicado: (2023)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis
por: Zhang, Yu-Fei, et al.
Publicado: (2023)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study
por: O'Hara, Montana, et al.
Publicado: (2021)

Attitudes towards Human Papilloma Virus Vaccination in the Latin American Andean Region
por: Nwanodi, Oroma
Publicado: (2017)

Weight-Loss Interventions and Levonorgestrel Intrauterine System Implantation for Early-Stage Endometrial Cancer and Atypical Endometrial Hyperplasia to Reduce Perioperative Risk of Severely Obese Patients
por: Isono-Taniguchi, Roze, et al.
Publicado: (2023)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system
por: Kim, Da Hee, et al.
Publicado: (2017)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Prognostic factors of oncologic outcomes after fertility-preservative management with progestin in early-stage of endometrial cancer
por: Roh, Hyun Jin, et al.
Publicado: (2021)

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium
por: Barr, Chloe E., et al.
Publicado: (2021)

Metformin for endometrial hyperplasia: a Cochrane protocol
por: Clement, Naomi S, et al.
Publicado: (2016)

Intrauterine device use and risk of endometrial cancer.
por: Parazzini, F., et al.
Publicado: (1994)

The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer
por: Guan, Jun, et al.
Publicado: (2022)

Medically unfit women with early-stage endometrial cancer treated with the levonorgestrel intrauterine system
por: Nikolopoulos, Manolis, et al.
Publicado: (2020)

Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial*
por: Ørbo, A, et al.
Publicado: (2014)

Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia
por: Shen, Ye, et al.
Publicado: (2022)

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
por: Uccella, Stefano, et al.
Publicado: (2022)

Skin Protective Nutraceuticals: The Current Evidence in Brief
por: Nwanodi, Oroma
Publicado: (2018)

The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia
por: Chen, Xiaojun
Publicado: (2019)

Pulsatile tinnitus related to progestin from intrauterine device()
por: Onishi, Ektor Tsuneo, et al.
Publicado: (2015)

Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis
por: Hu, Jia-Li, et al.
Publicado: (2022)

Preeclampsia-Eclampsia Adverse Outcomes Reduction: The Preeclampsia-Eclampsia Checklist
por: Nwanodi, Oroma B.
Publicado: (2016)

Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
por: Kim, Mi Kyoung, et al.
Publicado: (2020)

Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?
por: Dore, Molly, et al.
Publicado: (2021)

A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women
por: Dinnekere Ravi, Ramya, et al.
Publicado: (2021)

Endometrial hyperplasia as a risk factor of endometrial cancer
por: Nees, Lisa K., et al.
Publicado: (2022)

Clinical Evaluation of Li Brush Endometrial Samplers for Diagnosing Endometrial Lesions in Women With Intrauterine Devices
por: Han, Lu, et al.
Publicado: (2020)

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia
por: Shan, Weiwei, et al.
Publicado: (2014)

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins
por: Kulkarni, A., et al.
Publicado: (2023)

Therapeutic options for management of endometrial hyperplasia
por: Chandra, Vishal, et al.
Publicado: (2016)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

Response to comment on: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Promising clinical practices of metformin in women with PCOS and early-stage endometrial cancer
por: Shao, Ruijin, et al.
Publicado: (2014)

Differential Effects of the Hormonal and Copper Intrauterine Device on the Endometrial Transcriptome
por: Smith-McCune, Karen, et al.
Publicado: (2020)

Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis
por: Li, Miaomiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n7ues9kruu5pff8mc2irji555t